美股新聞 標題聯播 · 近 24 小時 336 則 · 29 個來源 · 最新 9/20 04:53
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · ROIV近 30 天 14 則 · 第 1 / 1 頁
- What Is Roivant Sciences (ROIV) Signaling With Its Positive PH ILD Trial Data?
- Roivant Sciences Ltd. (ROIV)’s Pulmonary Hypertension Breakthrough Could Transform Its Growth Story
- Company News for Sep 9, 2026
- Roivant (ROIV) Soars to All-Time High; Q2 Hedge Fund Holdings Surge 41%
- Top Midday Gainers
- Roivant Sciences Stock Soars as Lung Disease Drug Hits Goals
- Roivant Stock Surges on 'Robust' Data from Rare Lung Disease Candidate
- Dr. Gillian Cannon Joins Lindus Therapeutics’ Board as a Non-Executive Director
- Roivant Sciences' Pulmovant Reports Positive Phase 2 Results for Mosliciguat in PH-ILD
- Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
- Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
- What Lisraya’s $35,000 Monthly Price Could Mean for Roivant (ROIV)
- Roivant Wins Approval for the First Oral Dermatomyositis Drug. How Large is the Opportunity?
- Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026
- Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
- Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsight
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。